Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MED302
- Development stage
- Preclinical
- Lead developer
- Medley Therapeutics
- Modality
- Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
MED302 is an experimental multivalent antibody currently in the discovery stage for the treatment of solid tumors. Developed by Medley Therapeutics (formerly YAP Therapeutics) as part of its Advanced Biologics Platform, the drug is designed to address oncological indications. While Medley Therapeutics focuses heavily on the YAP/Hippo signaling pathway—a key regulator of organ size and tissue regeneration—the specific molecular target and binding characteristics of MED302 have not been publicly disclosed. The candidate is part of a pipeline that includes both genetic medicines and advanced biologics for regenerative medicine, fibrosis, and oncology.
Beyond the preview
Go deeper on MED302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MED302.